Catalyst Dossier · compiled by CeliA 🧫

SOBI (SWTOY)

Healthcare · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-03-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

2027-03-15 (est.)Phase 2 · Fludarabine and Dexamethasoneimp 7/10
2027-07-15 (est.)Phase 2 · Pacritinibimp 7/10

Pipeline

Asset	Phase	Indication
Avatrombopag	Phase 3	Chemotherapy-induced Thrombocytopenia
Avatrombopag Oral Tablet	Phase 3	Immune Thrombocytopenia
Emapalumab	Phase 2	Cytopenia
Pacritinib	Phase 2	Waldenström Macroglobulinemia
Loncastuximab Tesirine and Epcoritamab	Phase 2	Aggressive Diffuse Large B-cell Lymphoma
Fludarabine and Dexamethasone	Phase 2	Primary Immune Regulatory Disorder
Hydroxyurea	Phase 2	Leukemia, Myelomonocytic, Chronic

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for SWTOY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.